Wang S-P, Wang W-L, Chang Y-L,Wu C-T, Chao Y-C, Kao S-H, et al.Gain-of-function (GOF) mutant p53 as actionable therapeutic target. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong C, Hann B, et al.A mutant-p53/smad complex opposes p63 to empower TGFbeta-induced metastasis.Cold Spring Harbor Perspectives in Biology(2010) 2(2):a001107. Biochemical and Biophysical Research Communications(2001) 287(1):173–180. Comparisons of tumor suppressor p53, p21, and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Wang TJ, Huang MS, Hong CY, Tse V, Silverberg GD, Hsiao M.Telomerase promoter mutations in cancer: an emerging molecular biomarker?Virchows Archiv(2014) 465(2):119–133. Vinagre J, Pinto V, Celestino R, Reis M, Pópulo H, Boaventura P, et al.TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.Proceedings of the National Academy of Sciences of the United States of America(2013) 110(15):6021–6026. Nature(2012) 482(7384):226–231.Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, LA, Jr, Diaz, et al. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatricglioblastoma. Schwartzentruber J, Korshunov A, Liu X-Y, Jones D, Pfaff E, Jacob K. Neuro-oncology(2013) 2(Suppl 2):ii1-ii56.Īkçakoca and Küçükoğlu / Overview of Glioblastoma: Current Drugs and Novel Therapy Trends35 Ostrom QT, Gittleman H, Farah P, Ondracek A, Chen Y, Wolinsky Y, et al.CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2006–2010.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C.Trendsand patterns of incidence of diffuse glioma in adults in the United States: 1973-2014. Li K, Lu D, Guo Y, Wang C, Liu X, Liu Y.CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS.The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Louis DN, Perry A, Reifenberger G, Deimling A, Figarella-Branger D, Cavenee WK.The definition of primary and secondary glioblastoma. Australia:Brisbane: Codon Publications (2017). Epidemiology and outcome of glioblastoma. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2011-2015. Ostrom QT,Gittleman H, Truitt G, Boscia A, Kruchko C, Barnholtz-Sloan JS.Psychosocial and supportive-care needs in high-grade glioma. State of the science in brain tumor classsification. Understanding Pathophysiology, McKance KL. Nursing care of patients with central nervous system disorders. Hill CI, Nixon CS, Ruehmeier JL, Wolf LM.Common neurosurgical and neurological disorders Morton PG, Fontaine D, Hudak CM, Gallo BM, editors. Metastatic brain tumors: diagnosis, treatment, and nursing interventions. USA: Lippincott Williams & Wilkins (2005). Brunner & Suddarth’s textbook of medical-surgical nursing. The essential guide to brain tumors(2007). Journal of Neurology, Neurosurgery, and Psychiatry2(Suppl 2):ii12-ii17. Brain tumours: incidence, survival, and aetiology. In this paper, the characteristics of glioblastoma multiforme (GBM), its incidence, genetic pathogenesis, risk factors, treatment options and drugs used in chemotherapy, difficulties encountered in treatment, novel therapies for GBM and challenges and future directions are discussed. Targeted molecular (precision) therapies, targeting DNA damage response pathways, targeting tumor metabolism, immunotherapies, and viral therapies are novel treatment options being studied for the treatment of GBM. Temozolomide, carmustine, irinotecan and bevacizumab are the most important anticancer agents used in chemotherapy for GBM therapy. In GBM treatment, surgery, radiotherapy and chemotherapy are usually combined. It has been determined that ionizing radiation, obesity, some metals and chemicals, pesticides, TNF-α, IL-1 and IL-6 are risk factors of GBM. ATRX, TERT, TP53 mutations, loss of PTEN function, and EGFR and WT1 have been found to play a role in the genetic pathogenesis of GBM. GBM, a very aggressive tumor, has a low survival rate and currently has no curative treatment. Glioblastoma multiforme (GBM) is the most common type of malignant primary brain tumor.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |